Carregant...
Antibody inhibition of properdin prevents complement-mediated intravascular and extravascular hemolysis(1)
Paroxysmal nocturnal hemoglobinuria (PNH) is a serious blood disorder characterized by dysregulated complement activation on blood cells. Eculizumab, the current standard therapy and a humanized anti-C5 mAb relieves anemia and thrombosis symptoms of PNH patients by preventing complement-dependent in...
Guardat en:
| Publicat a: | J Immunol |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6057807/ https://ncbi.nlm.nih.gov/pubmed/29898960 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1800384 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|